Clinical Trials 2026: 3 Ways to Boost Enrollment

Getting enough people into a clinical trial enrollment is the single biggest brake on medical progress. As we move through 2026, the entire research community is still grappling with how to recruit and keep participants, and it’s directly slowing down how fast new treatments get to patients. So how do we actually fix this and get things moving?

Context and Background

The path from a lab discovery to an approved drug is a long, expensive slog, and patient enrollment is almost always the biggest holdup. For decades, trials were stuck in major academic medical centers, so if you didn’t live nearby or couldn’t take a ton of time off work, you were out of luck. This model automatically excluded huge numbers of people. A 2025 report from the NIH News confirmed that nearly 80% of clinical trials don’t hit their enrollment goals on time, which can delay new drugs by anywhere from six months to two years. That delay means real people are waiting for treatments that could help them. The COVID-19 pandemic, for all its tragedy, forced the issue by making decentralized trials a necessity, proving that remote monitoring and virtual visits are not only possible but often better for participants.

But you have to understand why enrollment is so low in the first place. For one, most people just don’t know that clinical trials are an option or where to find them. On top of that, historical ethical abuses have created a deep and justified distrust of the medical establishment, particularly within minority communities. You can’t fix that with a brochure. It requires genuine, long-term engagement to show that things have changed. Then there are the practical headaches: impossibly complex consent forms, appointment schedules that don’t work for anyone with a job, and not enough reimbursement for travel or lost wages. These are fundamental design flaws in the traditional research model.

Implications for Medical Progress

Faster clinical trial enrollment means faster medical progress. It’s that simple. When studies fill up on schedule, researchers get their answers sooner and can bring new drugs and devices to the people who need them. This is especially true for diseases where patients don’t have good options, like advanced cancers, neurodegenerative disorders, and rare genetic conditions. Just think about a new Alzheimer’s treatment getting held up an extra year because the trial can’t find enough participants, that’s a year of cognitive decline that patients and their families will never get back. Getting enrollment right also lowers the sky-high cost of drug development, since dragging out a trial costs a fortune in staff and site fees. That money can then be plowed back into more research. It’s a win-win.

And if you only test a drug on a narrow slice of the population, you have no real idea if it will work or be safe for everyone else, which is a massive scientific and ethical failure. We’re already seeing the effects of designing trials around the patient. Companies like Medidata Solutions are building platforms that handle things like remote patient monitoring and electronic consent, which takes a huge load off participants. At the same time, AI is digging through electronic health records to find eligible patients, which is a huge step up from the old way of manually sifting through charts. In fact, a 2025 article in the NEJM found this approach boosted enrollment rates by 25% in some oncology trials. This is happening right now, and it’s changing how research gets done.

These new methods are especially powerful in fields like the dermatology’s 2026 AI & Biologics revolution, where matching patients with very specific skin conditions to the right trial can dramatically speed things up. It’s the same story for psoriasis treatment innovations for patients and major research efforts like UT Southwestern’s cancer treatment revolution, none of it moves forward without people actually participating in the trials.

What’s Next

The future of medical research depends on finding even better ways to get patients enrolled. We expect to see a lot more community-based outreach, especially programs aimed at groups that have been left out of research in the past. We’re seeing this work in places like Atlanta, where Emory Healthcare and Grady Health System are partnering with local clinics to build relationships and trust on the ground. Even the FDA is adapting, issuing new guidance documents that support decentralized trial methods. For example, their 2025 guidance on “Enhancing Diversity in Clinical Trials” FDA Guidance is now pushing sponsors to come up with concrete plans to recruit a representative patient population.

Digital health tech is going to become even more baked into the process. Wearable sensors, mobile apps, and telehealth platforms will become standard tools, meaning fewer trips to the clinic. It’s easy to imagine a future where someone can participate in a trial for a chronic condition almost entirely from home, with their data flowing securely to the research team. This helps the patient, and it helps the clinical sites manage more studies at once. Of course, this evolution creates its own headaches, particularly around data privacy and digital literacy. (Not everyone is a tech whiz.) Making sure everyone has access to these tools and gets the support they need to use them will be essential. We also have to keep telling people about the ethical safeguards in place for research, making it clear that participation is always voluntary and their safety comes first. Trust is everything. Without it, nobody signs up.

This isn’t a problem one group can solve alone. It’s going to take a real effort from researchers, pharmaceutical companies, regulatory agencies, and patient advocacy groups working together to tear down the old barriers to enrollment. By focusing on what patients actually need, using technology smartly, and being transparent, we can speed up the whole process and get life-changing treatments to the people who are waiting for them.